Evofem Biosciences Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Evofem Biosciences has been growing earnings at an average annual rate of 27.3%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 53.7% per year.
Belangrijke informatie
27.3%
Groei van de winst
51.2%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 6.0% |
| Inkomstengroei | 53.7% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | 323.8% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Evofem partners with a360 Media to support Phexxi prescription growth
Jul 21Evofem announces peer-reviewed publication on birth control method
Jul 12Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier
Jul 06Evofem announces U.S. patent win for birth control method
Jun 30Evofem: ACA Coverage Of Phexxi Is A Game Changer
Jan 18Opbrengsten en kosten
Hoe Evofem Biosciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 18 | 57 | 22 | 3 |
| 31 Mar 24 | 16 | 47 | 24 | 3 |
| 31 Dec 23 | 18 | 50 | 27 | 3 |
| 30 Sep 23 | 14 | 44 | 31 | 3 |
| 30 Jun 23 | 15 | 67 | 43 | 8 |
| 31 Mar 23 | 18 | -48 | 57 | 15 |
| 31 Dec 22 | 17 | -78 | 72 | 25 |
| 30 Sep 22 | 20 | -119 | 92 | 32 |
| 30 Jun 22 | 16 | -283 | 110 | 35 |
| 31 Mar 22 | 11 | -192 | 122 | 36 |
| 31 Dec 21 | 8 | -206 | 138 | 33 |
| 30 Sep 21 | 5 | -194 | 138 | 30 |
| 30 Jun 21 | 3 | -150 | 124 | 25 |
| 31 Mar 21 | 2 | -169 | 110 | 20 |
| 31 Dec 20 | 0 | -142 | 87 | 17 |
| 30 Sep 20 | 0 | -114 | 66 | 14 |
| 30 Jun 20 | 0 | -98 | 53 | 16 |
| 31 Mar 20 | 0 | -81 | 40 | 18 |
| 31 Dec 19 | 0 | -80 | 31 | 22 |
| 30 Sep 19 | 0 | -82 | 27 | 28 |
| 30 Jun 19 | 0 | -87 | 27 | 32 |
| 31 Mar 19 | 0 | -75 | 31 | 39 |
| 31 Dec 18 | 0 | -126 | 34 | 43 |
| 30 Sep 18 | 0 | -131 | 33 | 45 |
| 30 Jun 18 | 0 | -188 | 27 | 41 |
| 31 Mar 18 | 0 | -172 | 18 | 33 |
| 31 Dec 17 | 0 | -109 | 12 | 24 |
| 30 Sep 17 | 0 | -103 | 11 | 17 |
| 31 Dec 16 | 0 | -69 | 15 | 15 |
Kwaliteitswinsten: EVFM has a large one-off gain of $76.5M impacting its last 12 months of financial results to 30th June, 2024.
Groeiende winstmarge: EVFM's current net profit margins are lower than last year .
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: EVFM has become profitable over the past 5 years, growing earnings by 27.3% per year.
Versnelling van de groei: EVFM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: EVFM had negative earnings growth (-14.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.4%).
Rendement op eigen vermogen
Hoge ROE: EVFM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.